, Volume 24, Issue 3, pp 213–217 | Cite as

High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients

  • D. Hober
  • Samira Benyoucef
  • Anne-Sophie Delannoy
  • P. Wattré
  • D. De Groote
  • Faïza Ajana
  • Y. Mouton


Plasma concentrations of soluble receptors for tumor necrosis factor type II (sTNFRII) and CD4+ lymphocyte counts were determined in patients with HIV-1 infection grouped according to the 1993 classification of the CDC. Compared with healthy controls (mean ± SD= 2.83±0.70 ng/ml; n=20), higher values of sTNFRII were obtained in most of patients of all groups of HIV-1-infected patients. The levels of sTNFRII were 5.29±1.75 ng/ml (n=23) for stage A1 patients, 5.27±2.25 ng/ml (n=37) for stage A2 patients, 6.03±1.9 ng/ml (n=14) for stage A3 patients, 7.41±3.25 ng/ml (n=21) for stage B and stage C patients. Intra-individual variance in sTNFRII levels in eight clinically stable patients with HIV-1 infection was observed in the course of a short-time follow-up. The increase of sTNFRII plasma levels in five out of ten patients was shown at time lapses of 3 years. In contrast to previous reports no inverse correlation between sTNFRII and CD4+ lymphocyte counts was found in all stages of disease. The increased level of sTNFRII in circulating blood might reflect the activation of the TNFα system. These results support an activation of this system occurring early in the course of HIV infection.


Tumor Necrosis Factor Lymphocyte Count Time Lapse Tumor Necrosis Factor Receptor Soluble Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Plasmakonzentration des löslichen Tumornekrosefaktor-Rezeptor Typ II (sTNFRII) bei Patienten mit HIV-1-Infektion


Bei Patienten mit HIV-1-Infektion, eingeteilt nach der CDC-Klassifikation, wurde der Tumornekrosefaktor-Rezeptor Typ II (sTNFRII) und der Anteil zirkulierender CD4+ Lymphozyten bestimmt. Im Vergleich zur gesunden Kontrollgruppe (Mittelwert ± Standardabweichung 2,83±0,70 ng/ml) sind die Werte für sTNFRII bei den meisten Patienten in allen Infektionsstadien höher. Die Konzentrationen für sTNFRII liegen bei 5,29±1,75 ng/ml (n=23) bei Patienten im Stadium A1; bei 5,27±2,25 ng/ml (n=37) bei Patienten im Stadium A2; bei 6,03±1,9 ng/ml (n=14) bei Patienten im Stadium A3 und bei 7,41±3,25 ng/ml (n=21) bei Patienten im Stadium B und im Stadium C. Wir stellten eine intraindividuelle Variabilität des sTNFRII Spiegel bei acht klinisch stabilen HIV-infizierten Patienten im Verlauf eines kurzen Beobachtungszeitraums fest. Wir konnten einen Anstieg des sTNFRII Spiegel in Plasmaproben in einem Zeitintervall von 3 Jahren beobachten. Im Gegensatz zu anderen Ergebnissen fanden wir in den verschiedenen Infektionsstadien keine inverse Korrelation zwischen dem sTNFRII und dem CD4+ Lymphozytenanteil. Der Anstieg der zirkulierenden sTNFRII-Konzentration könnte eine Aktivierung des TNFα-Systems widerspiegeln. Unsere Ergebnisse sprechen für eine Aktivierung dieses Systems zu einem frühen Zeitpunkt der HIV-Infektion.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fauci, A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 239 (1988) 617–622.PubMedGoogle Scholar
  2. 2.
    Matsuyama, T., Kobayashi, N., Yamamoto, N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 5 (1991) 1405–1417.PubMedGoogle Scholar
  3. 3.
    Hober, D., Lucas, B., Wattré, P., Capron, A., Haque, A. TNFα production by U937 promonocytes is enhanced by factors released from HIV-infected T4 lymphocytes: TNFα is one of the mediators causing lysis of HIV-infected T4 cells. Clin. Immunol. Immunopathol. 62 (1992) 168–175.PubMedGoogle Scholar
  4. 4.
    Lahdevista, J., Maury, C. P. J., Teppo, A., Repo, H. Elevated levels of circulating cachectin tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am. J. Med. 85 (1988) 289–291.PubMedGoogle Scholar
  5. 5.
    Hober, D., Haque, A., Wattré, P., Beaucaire, G., Mouton, Y., Capron, A. Production of tumor necrosis factor (TNFα) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNFα is related to a higher cytotoxic activity. Clin. Exp. Immunol. 78 (1989) 329–333.PubMedGoogle Scholar
  6. 6.
    Roux-Lombard, P., Modoux, C., Cruchaud, A., Dayer, J. M. Purified blood monocytes from HIV 1 infected patients produce high levels of TNFα and IL-1. Clin. Immunol. Immunopathol. 50 (1989) 374–384.PubMedGoogle Scholar
  7. 7.
    Wright, S. C., Jewett, A., Mitsuyasu, R., Bonavida, B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J. Immunol. 14 (1988) 99–104.Google Scholar
  8. 8.
    Reddy, M. M., Sorrell, S. J., Lange, M., Grieco, M. H. Tumor necrosis factor and HIV p24 antigen levels in serum of HIV-infected populations. J. Acquir. Immune Defic. Syndr. 1 (1988) 436–440.PubMedGoogle Scholar
  9. 9.
    Kalinkovich, A., Engelmann, H., Harpaz, N., Burstein, R., Barak, V., Kalickman, I., Wallach, D., Bentwich, Z. Elevated serum levels of soluble tumor necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin. Exp. Immunol. 89 (1992) 351–355.PubMedGoogle Scholar
  10. 10.
    Godfried, M. H., van der Poll, T., Jansen, J., Romijin, J. A., Eeftinck Schattenkerk, J. K. M., Endert, E., van Deventer, S. J. H., Sauerwein, H. P. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS 7 (1993) 33–36.PubMedGoogle Scholar
  11. 11.
    Aukrust, P., Liabakk, N. B., Muller, F., Lien, E., Espevik, T., Frøland, S.: Serum levels of tumor necrosis factor-α (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection — correlations to clinical, immunologic, and virologic parameters. J. Infect. Dis. 169 (420–424).Google Scholar
  12. 12.
    Zangerle, R., Gallati, H., Sarcletti, M., Weiss, G., Denz, H., Wachter, H., Fuchs, D. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J. Acquir. Immune Defic. Syndr. 7 (1994) 79–85.PubMedGoogle Scholar
  13. 13.
    Godfried, M. H., van der Poll, T., Weverling, G. J., Mulder, J. W., Jansen, J., van Deventer, S. J. H., Sauerwein, H. P. Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J. Infect. Dis. 169 (1994) 739–745.PubMedGoogle Scholar
  14. 14.
    Aukrust, P., Liabakk, N.-B., Müller, F., Espevik, T., Frøland, S. S. Activation of tumor necrosis factor-α system in HIV-1 infection: association with markers of immune activation. Infection 23 (1995) 9–15.PubMedGoogle Scholar
  15. 15.
    Centers for Diseases Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 (1992) 1–19.Google Scholar
  16. 16.
    Fahey, J. L., Taylor, J. M. G., Detels, R., Hofman, B., Melmed, R., Nishanian, P., Giorgi, J. V. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322 (1990) 166–172.PubMedGoogle Scholar
  17. 17.
    Lantz, M., Malik, S., Slevin, M. L., Olsson, I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2 (1990) 406.Google Scholar
  18. 18.
    Scott-Alagara, S. D., Vuillier, F., Marasescu, M., De Saint Martin, J., Dignero, G. Serum levels of Il-2, Il-1 and TNFα and soluble receptor of Il-2 in HIV-1 infected patients. AIDS Res. and Hum. Retrovirus. 7 (1991) 381–386.Google Scholar
  19. 19.
    Jones, P. D., Shelley, L., Wakefield, D. Tumor necrosis factor-α in advanced HIV infection in the absence of AIDS-related secondary infections. J. Acquir. Immune Defic. Syndr. 5 (1992) 1266–1271.PubMedGoogle Scholar
  20. 20.
    Hober, D., Ajana, F., Petit, M. C., Sartiaux, C., Boniface, M., Caillaux, M., Mouton, Y., Wattré, P., Maniez-Montreuil, M. Granulocyte-macrophage colony stimulating factor and tumor necrosis factor α in patients with human immunodeficiency virus (HIV) type 1 infection. Microbiol. Immunol. 37 (1993) 785–792.PubMedGoogle Scholar
  21. 21.
    Aderka, D., Engelmann, H., Shemer-Avni, Y., Hornik, V., Galil, A., Sarov, B., Wallach, D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res. 11 (1992) 157–159.PubMedGoogle Scholar
  22. 22.
    Rimaniol, A.-C., Boussin, F., Herbelin, A., De Groote, D., Dormont, D., Bach, J.-F., Descamps-Latscha, B., Zavala, F. Induction of soluble tumor necrosis factor receptor (sTNF-Rp75) release by HIV adsorption on cultured human monocytes. Eur. J. Immunol. 24 (1994) 2055–2060.PubMedGoogle Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1996

Authors and Affiliations

  • D. Hober
    • 1
  • Samira Benyoucef
    • 1
  • Anne-Sophie Delannoy
    • 1
  • P. Wattré
    • 1
  • D. De Groote
    • 2
  • Faïza Ajana
    • 3
  • Y. Mouton
    • 3
  1. 1.Laboratoire de VirologieBât. IRFPPS, CHULille CedexFrance
  2. 2.Dept. of Research and DevelopmentMedgenix Diagnostics SAFleurusBelgium
  3. 3.Service Régional des Maladies InfectieusesHôpital DronTourcoingFrance

Personalised recommendations